Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 6, 2009, Pages 1773-1778

  Ortega, Raquel ^a   Raviña, Enrique ^a   Masaguer, Christian F ^a   Areias, Filipe ^a   Brea, José ^a   Loza, María I ^a   López, Laura ^b   Selent, Jana ^b   Pastor, Manuel ^b   Sanz, Ferran ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Antipsychotics; Arylpiperazines; Benzolactams; Dopamine receptors; Structure activity relationship

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BENZOLACTAM DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LACTAM DERIVATIVE; SEROTONIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINONES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; KINETICS; LACTAMS; LIGANDS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PIPERAZINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61349150703     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.067     Document Type: Article

References (43)

1. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Physiol. Rev. 78 (1998) 189
2. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwartz J.C. Nature 347 (1990) 146
3. Levant B. Pharmacol. Rev. 49 (1997) 231
4. Joyce J.N., and Miador-Woodruff J.H. Neuropsychopharmacology 16 (1997) 375
5. Shafer R.A., and Levant B. Psychopharmacology 135 (1998) 1
6. Joyce J.N. Pharmacol. Ther. 90 (2001) 231
7. Joyce J.N., and Millan M.J. Drug Discov. Today 10 (2005) 917
8. Strange P.G. Adv. Drug Res. 28 (1996) 313
9. Kapur S., and Mamo D. Prog. Neuro-Psychopharm. Biol. Psychiatry 27 (2003) 1081
10. Leriche L., Scharz J.-C., and Sokoloff P. Neuropharmacology 45 (2003) 174
11. Roth B.L., Sheffler D.J., and Kroeze W.K. Nat. Rev. Drug Discov. 3 (2004) 353
12. Spedding M., Jay T., Costa e Silva J., and Perret L. Nat. Rev. Drug Discov. 4 (2005) 467
13. Nasrallah H.A. Mol. Psychiatry 13 (2008) 27
14. Meltzer H.Y. CNS Spectrosc. 9 (2004) 15
15. Bezard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., and Sokoloff P. Nat. Med. 9 (2003) 762
16. Boeckler F., and Gmeiner P. Pharmacol. Ther. 112 (2006) 281
17. Luedtkea R.R., and Mach R.H. Curr. Pharm. Des. 9 (2003) 643
18. Crider A.M., and Scheideler M.A. Mini Rev. Med. Chem. 1 (2001) 89
19. Pilla M., Perachon S., Sautel F., Garridol F., Mann A., Wermuth C.G., Schwartz J.-C., Everitt B.J., and Sokoloff P. Nature 400 (1999) 371
20. Wicke K., and Garcia-Ladona J. Eur. J. Pharmacol. 424 (2001) 85
21. Bettinetti L., Schlotter K., Huebner H., and Gmeiner P. J. Med. Chem. 45 (2002) 459
22. Millan M.J., Loiseau F., Dekeyne A., Gobert A., Flik G., Cremers T.I., Rivet J.-M., Sicard D., Billiras R., and Brocco M. J. Pharmacol. Exper. Ther. 324 (2008) 1212
23. Hacling A.E., and Stark H. ChemBioChem 3 (2002) 946
24. Tomita M., Minami S., and Uyeo S. J. Chem. Soc. (1969) 183
25. Conley R.T. J. Org. Chem. 23 (1958) 1330
26. Evans D., and Lockhart I.M. J. Chem. Soc. (1965) 4806
27. Grunewald G.L., and Dahanukar V.H. J. Heterocyclic Chem. 31 (1994) 1609
28. Mach U.R., Hackling A.E., Perachon S., Ferry S., Wermuth C.G., Schwartz J.-C., Sokoloff P., and Stark H. ChemBioChem 5 (2004) 508
29. Hackling A., Ghosh R., Perachon S., Mann A., Höltje H.-D., Wermuth C.G., Schwartz J.-C., Sippl W., Sokoloff P., and Stark H. J. Med. Chem. 46 (2003) 3883
30. Norman M.H., Rigdon G.C., Navas III F., and Cooper B.R. J. Med. Chem. 37 (1994) 2552
31. Brea J., Castro M., Loza M.I., Masaguer C.F., Raviña E., Dezi C., Pastor M., Sanz F., Cabrero-Castel A., Galán-Rodríguez B., Fernández-Espejo E., Maldonado R., and Robledo P. Neuropharmacology 51 (2006) 261
32. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099
33. Selent J., López L., Sanz F., and Pastor M. ChemMedChem 3 (2008) 1194
34. Ballesteros J., and Weinstein H. Methods Neurosci. 25 (1995) 366
35. Simpson M.M., Ballesteros J.A., Chiappa V., Chen J., Suehiro M., Hartman D.S., Godel T., Snyder L.A., Sakmar T.P., and Javitch J.A. Mol. Pharmacol. 56 (1999) 1116
36. Shi L., and Javitch J.A. Proc. Natl. Acad. Sci. USA 101 (2004) 440
37. Boeckler F., and Gmeiner P. Biochim. Biophys. Acta 1768 (2007) 871
38. Ceulemans D.L.S., Gelders Y.G., Hoppenbrouwers M.-L.J.A., Reyntjens A.J.M., and Janssen P.A.J. Psychopharmacology 85 (1985) 329
39. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., and Gross C. CNS Neurol. Disord. Drug Targets 5 (2006) 25
40. +, 0.28), 245 (100), 174 (20).
41. Meltzer H.Y., Matsubara S., and Lee J.C. Psychopharmacol. Bull. 25 (1989) 390
42. Roth B.L., Tandra S., Burgess L.H., Sibley D.R., and Meltzer H.Y. Psychopharmacology 120 (1995) 365
43. Roth B.L., Meltzer H.Y., and Khan N. Adv. Pharmacol. 42 (1998) 482